| 000 | 01636 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517090352.0 | ||
| 264 | 0 | _c20170907 | |
| 008 | 201709s 0 0 eng d | ||
| 022 | _a1872-9142 | ||
| 024 | 7 |
_a10.1016/j.molimm.2016.03.011 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhang, Li | |
| 245 | 0 | 0 |
_aTfh cell-mediated humoral immune response and HBsAg level can predict HBeAg seroconversion in chronic hepatitis B patients receiving peginterferon-α therapy. _h[electronic resource] |
| 260 |
_bMolecular immunology _c05 2016 |
||
| 300 |
_a37-45 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFlow Cytometry |
| 650 | 0 | 4 |
_aHepatitis B Surface Antigens _xblood |
| 650 | 0 | 4 |
_aHepatitis B e Antigens _xblood |
| 650 | 0 | 4 |
_aHepatitis B, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunity, Humoral _ximmunology |
| 650 | 0 | 4 |
_aInterferon-alpha _xtherapeutic use |
| 650 | 0 | 4 | _aLongitudinal Studies |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aSeroconversion _xdrug effects |
| 650 | 0 | 4 |
_aT-Lymphocytes, Helper-Inducer _ximmunology |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aZhang, Miao | |
| 700 | 1 | _aLi, Hu | |
| 700 | 1 | _aChen, Zhiwei | |
| 700 | 1 | _aLuo, Aoran | |
| 700 | 1 | _aLiu, Bin | |
| 700 | 1 | _aChen, Min | |
| 700 | 1 | _aPeng, Mingli | |
| 700 | 1 | _aRen, Hong | |
| 700 | 1 | _aHu, Peng | |
| 773 | 0 |
_tMolecular immunology _gvol. 73 _gp. 37-45 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.molimm.2016.03.011 _zAvailable from publisher's website |
| 999 |
_c25886253 _d25886253 |
||